OTLC
Oncotelic Therapeutics, Inc.0.0900
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
39.83MP/E (TTM)
-Basic EPS (TTM)
-0.01Dividend Yield
0%Recent Filings
8-K
Secured note to Mast Hill
Oncotelic Therapeutics entered a securities purchase agreement with Mast Hill Fund on January 23, 2026, issuing a $398,333.33 convertible note (10% OID, $358,500 cash proceeds) at $0.07/share conversion and 1,422,613 warrants at $0.15 exercise, secured by most assets but excluding joint venture tech. Proceeds fund working capital. Note matures in one year; dilution risk looms large.
8-K
CEO incentive RSA signed
Oncotelic Therapeutics entered a restricted stock agreement on January 22, 2026, with CEO Dr. Vuong Trieu, granting up to 26,512 shares of Series A Preferred Stock—convertible into 26.5M common shares—for hitting capital structure milestones. First milestone achieved: converting $2.175M 2023 PPM Notes into 2025 Units, vesting 4,426 preferred shares. Remaining vestings hinge on $350K+ Mast Hill debt plus $45M market cap, $3.3M related-party loan conversion, and $2.175M repayment. Ties CEO pay to deleveraging.
8-K
CEO RSA milestone lowered
Oncotelic Therapeutics amended its CEO Dr. Vuong Trieu's restricted stock agreement on January 2, 2026, slashing the first milestone threshold from $100 million to $45 million market cap on a single trading day's close. A parallel tweak hit Jefferson Capital Ventures' contractor deal. This eases equity grants. Progress builds via Mast Hill equity line and AGP financing.
8-K
Milestone threshold cut to $45M
Oncotelic Therapeutics amended its August 2025 independent contractor agreement with Jefferson Capital Ventures on December 31, 2025, slashing the first milestone's market cap threshold from $100 million to $45 million for restricted stock awards. This eases equity grants while the company advances its Mast Hill equity line, AGP financing, and Sichenzia Ross uplisting efforts. Progress continues.
8-K
Closes final $1.1M tranche
Oncotelic Therapeutics closed Tranche 3 of its unit offering on December 31, 2025, issuing 44 units worth $1.1M principal to 22 accredited investors, wrapping up the 500-unit program. Each unit packs a $25,000 12% note convertible to Oncotelic or EdgePoint shares, plus matching warrants. Final tranche bolsters liquidity. Notes mature in two years post-closing.
CNTA
Centessa Pharmaceuticals plc
25.72-0.43
EXEL
Exelixis, Inc.
41.60+0.22
GRTX
Galera Therapeutics, Inc.
0.02+0.00
LTRN
Lantern Pharma Inc.
3.33-0.04
OGEN
Oragenics Inc.
0.83-0.01
OKUR
OnKure Therapeutics, Inc.
3.02-0.18
ONCY
Oncolytics Biotech Inc.
1.04+0.12
ORIC
Oric Pharmaceuticals, Inc.
9.12-0.11
OTLK
Outlook Therapeutics, Inc.
2.47+0.30
ZNTL
Zentalis Pharmaceuticals, Inc.
1.38-0.02